Additional file 4 of ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy
Additional file 4: Figure S4. No change in the mouse body weight between control and treated groups throughout the treatment. No impact of bufalin on the organ/body weight ratio (p>0.05).
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , |
|---|---|
| Format: | Bild |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | Soumoy, Laura Genbauffe, Aline Mouchart, Lena Sperone, Alexandra Trelcat, Anne Mukeba-Harchies, Léa Wells, Mathilde Blankert, Bertrand Najem, Ahmad Ghanem, Ghanem Saussez, Sven Journe, Fabrice |
| description | Additional file 4: Figure S4. No change in the mouse body weight between control and treated groups throughout the treatment. No impact of bufalin on the organ/body weight ratio (p>0.05). |
| doi_str_mv | 10.6084/m9.figshare.26660837 |
| format | Image |
| fullrecord | <record><control><sourceid>datacite_PQ8</sourceid><recordid>TN_cdi_datacite_primary_10_6084_m9_figshare_26660837</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>10_6084_m9_figshare_26660837</sourcerecordid><originalsourceid>FETCH-datacite_primary_10_6084_m9_figshare_266608373</originalsourceid><addsrcrecordid>eNqdj01KxEAQRrNxIeoNXHwXMCZOyDjLQRSXLmbfVJLqpKB_QneJ5Eqe0h6YuYCrguJ7PF5VPbZN3Tev3bM_1FbmvFDi-qXvy2-3v61-j9MkKjGQgxXH6BAtjqev9thCMghril6yhBmBf6CUZlbYmODZUYieoIlJPQcFhQkjBQwMCYsMojxh2CCasS5blujiLGNxOZnP4-HbkpMAjUicNSa-GAqnCydaN7C1BRm3--qmjDM_XO5d1X28n94-nyZSGovKrEk8pc20jTknG38w12RzTd79E_sDPhxtFw</addsrcrecordid><sourcetype>Publisher</sourcetype><iscdi>true</iscdi><recordtype>image</recordtype></control><display><type>image</type><title>Additional file 4 of ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy</title><source>DataCite</source><creator>Soumoy, Laura ; Genbauffe, Aline ; Mouchart, Lena ; Sperone, Alexandra ; Trelcat, Anne ; Mukeba-Harchies, Léa ; Wells, Mathilde ; Blankert, Bertrand ; Najem, Ahmad ; Ghanem, Ghanem ; Saussez, Sven ; Journe, Fabrice</creator><creatorcontrib>Soumoy, Laura ; Genbauffe, Aline ; Mouchart, Lena ; Sperone, Alexandra ; Trelcat, Anne ; Mukeba-Harchies, Léa ; Wells, Mathilde ; Blankert, Bertrand ; Najem, Ahmad ; Ghanem, Ghanem ; Saussez, Sven ; Journe, Fabrice</creatorcontrib><description>Additional file 4: Figure S4. No change in the mouse body weight between control and treated groups throughout the treatment. No impact of bufalin on the organ/body weight ratio (p>0.05).</description><identifier>DOI: 10.6084/m9.figshare.26660837</identifier><language>eng</language><publisher>figshare</publisher><subject>Biological Sciences not elsewhere classified ; Biotechnology ; Cancer ; Cell Biology ; Developmental Biology ; Hematology ; Medicine ; Molecular Biology ; Pharmacology ; Space Science</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>776,1888</link.rule.ids><linktorsrc>$$Uhttps://commons.datacite.org/doi.org/10.6084/m9.figshare.26660837$$EView_record_in_DataCite.org$$FView_record_in_$$GDataCite.org$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Soumoy, Laura</creatorcontrib><creatorcontrib>Genbauffe, Aline</creatorcontrib><creatorcontrib>Mouchart, Lena</creatorcontrib><creatorcontrib>Sperone, Alexandra</creatorcontrib><creatorcontrib>Trelcat, Anne</creatorcontrib><creatorcontrib>Mukeba-Harchies, Léa</creatorcontrib><creatorcontrib>Wells, Mathilde</creatorcontrib><creatorcontrib>Blankert, Bertrand</creatorcontrib><creatorcontrib>Najem, Ahmad</creatorcontrib><creatorcontrib>Ghanem, Ghanem</creatorcontrib><creatorcontrib>Saussez, Sven</creatorcontrib><creatorcontrib>Journe, Fabrice</creatorcontrib><title>Additional file 4 of ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy</title><description>Additional file 4: Figure S4. No change in the mouse body weight between control and treated groups throughout the treatment. No impact of bufalin on the organ/body weight ratio (p>0.05).</description><subject>Biological Sciences not elsewhere classified</subject><subject>Biotechnology</subject><subject>Cancer</subject><subject>Cell Biology</subject><subject>Developmental Biology</subject><subject>Hematology</subject><subject>Medicine</subject><subject>Molecular Biology</subject><subject>Pharmacology</subject><subject>Space Science</subject><fulltext>true</fulltext><rsrctype>image</rsrctype><creationdate>2024</creationdate><recordtype>image</recordtype><sourceid>PQ8</sourceid><recordid>eNqdj01KxEAQRrNxIeoNXHwXMCZOyDjLQRSXLmbfVJLqpKB_QneJ5Eqe0h6YuYCrguJ7PF5VPbZN3Tev3bM_1FbmvFDi-qXvy2-3v61-j9MkKjGQgxXH6BAtjqev9thCMghril6yhBmBf6CUZlbYmODZUYieoIlJPQcFhQkjBQwMCYsMojxh2CCasS5blujiLGNxOZnP4-HbkpMAjUicNSa-GAqnCydaN7C1BRm3--qmjDM_XO5d1X28n94-nyZSGovKrEk8pc20jTknG38w12RzTd79E_sDPhxtFw</recordid><startdate>20240814</startdate><enddate>20240814</enddate><creator>Soumoy, Laura</creator><creator>Genbauffe, Aline</creator><creator>Mouchart, Lena</creator><creator>Sperone, Alexandra</creator><creator>Trelcat, Anne</creator><creator>Mukeba-Harchies, Léa</creator><creator>Wells, Mathilde</creator><creator>Blankert, Bertrand</creator><creator>Najem, Ahmad</creator><creator>Ghanem, Ghanem</creator><creator>Saussez, Sven</creator><creator>Journe, Fabrice</creator><general>figshare</general><scope>DYCCY</scope><scope>PQ8</scope></search><sort><creationdate>20240814</creationdate><title>Additional file 4 of ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy</title><author>Soumoy, Laura ; Genbauffe, Aline ; Mouchart, Lena ; Sperone, Alexandra ; Trelcat, Anne ; Mukeba-Harchies, Léa ; Wells, Mathilde ; Blankert, Bertrand ; Najem, Ahmad ; Ghanem, Ghanem ; Saussez, Sven ; Journe, Fabrice</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-datacite_primary_10_6084_m9_figshare_266608373</frbrgroupid><rsrctype>images</rsrctype><prefilter>images</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Biological Sciences not elsewhere classified</topic><topic>Biotechnology</topic><topic>Cancer</topic><topic>Cell Biology</topic><topic>Developmental Biology</topic><topic>Hematology</topic><topic>Medicine</topic><topic>Molecular Biology</topic><topic>Pharmacology</topic><topic>Space Science</topic><toplevel>online_resources</toplevel><creatorcontrib>Soumoy, Laura</creatorcontrib><creatorcontrib>Genbauffe, Aline</creatorcontrib><creatorcontrib>Mouchart, Lena</creatorcontrib><creatorcontrib>Sperone, Alexandra</creatorcontrib><creatorcontrib>Trelcat, Anne</creatorcontrib><creatorcontrib>Mukeba-Harchies, Léa</creatorcontrib><creatorcontrib>Wells, Mathilde</creatorcontrib><creatorcontrib>Blankert, Bertrand</creatorcontrib><creatorcontrib>Najem, Ahmad</creatorcontrib><creatorcontrib>Ghanem, Ghanem</creatorcontrib><creatorcontrib>Saussez, Sven</creatorcontrib><creatorcontrib>Journe, Fabrice</creatorcontrib><collection>DataCite (Open Access)</collection><collection>DataCite</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Soumoy, Laura</au><au>Genbauffe, Aline</au><au>Mouchart, Lena</au><au>Sperone, Alexandra</au><au>Trelcat, Anne</au><au>Mukeba-Harchies, Léa</au><au>Wells, Mathilde</au><au>Blankert, Bertrand</au><au>Najem, Ahmad</au><au>Ghanem, Ghanem</au><au>Saussez, Sven</au><au>Journe, Fabrice</au><format>book</format><genre>unknown</genre><ristype>GEN</ristype><title>Additional file 4 of ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy</title><date>2024-08-14</date><risdate>2024</risdate><abstract>Additional file 4: Figure S4. No change in the mouse body weight between control and treated groups throughout the treatment. No impact of bufalin on the organ/body weight ratio (p>0.05).</abstract><pub>figshare</pub><doi>10.6084/m9.figshare.26660837</doi><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | DOI: 10.6084/m9.figshare.26660837 |
| ispartof | |
| issn | |
| language | eng |
| recordid | cdi_datacite_primary_10_6084_m9_figshare_26660837 |
| source | DataCite |
| subjects | Biological Sciences not elsewhere classified Biotechnology Cancer Cell Biology Developmental Biology Hematology Medicine Molecular Biology Pharmacology Space Science |
| title | Additional file 4 of ATP1A1 is a promising new target for melanoma treatment and can be inhibited by its physiological ligand bufalin to restore targeted therapy efficacy |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-28T20%3A26%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-datacite_PQ8&rft_val_fmt=info:ofi/fmt:kev:mtx:book&rft.genre=unknown&rft.au=Soumoy,%20Laura&rft.date=2024-08-14&rft_id=info:doi/10.6084/m9.figshare.26660837&rft_dat=%3Cdatacite_PQ8%3E10_6084_m9_figshare_26660837%3C/datacite_PQ8%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |